Promosome was founded in 2003 to commercialize discoveries at The Scripps Research Institute by the late Nobel Laureate Dr. Gerald Edelman and his colleague Dr. Vincent Mauro, now Chief Scientific Officer and Senior Vice-President at Promosome. Their basic research on mechanisms of mRNA translation had clear applications for optimizing protein expression and purity in the burgeoning field of protein biotherapeutics.
The technologies involve recoding mRNAs for biotherapeutic agents to enhance ribosome recruitment, eliminate false starts in translation initiation, and ensure message stability in both eukaryotic and prokaryotic cells. Because the alterations are performed in a manner consistent with the natural mRNA counterparts in the human body, they minimizing the risk of negative clinical outcomes associated with synonymous mutations introduced by the routinely used codon optimization paradigms.
The company is privately held with headquarters in New York City and research facilities in San Diego.